New applications include Veeva LIMS Basics and PromoMats Basics to drive speed and growth
/PRNewswire/ –Veeva Systems (NYSE: VEEV) today announced that more than 100 biotechnology companies have chosen Veeva Basics to scale clinical, regulatory and quality operations. A growing number of biotechnology companies in the United States and Europe are establishing the foundation for growth with a simple, standard solution that can adapt to changing business needs.
With Veeva Basics, biotechnology companies benefit from best-in-class industrial applications pre-configured and pre-validated for rapid deployment. Veeva Basics is built on the Vault platform, allowing biotech companies to move to a complete Vault solution without any migration. This gives businesses the technology and support to build effective processes in key business areas now and in the long term.
“More than 100 biotechnology leaders from 60 companies gathered at the Veeva Research, Development and Quality Summit in Boston to learn, connect and shape the future of Veeva Basics. We are proud of the impact that Veeva Basics is having on emerging biotechnology companies and we will continue to add new innovative applications that can be implemented quickly to support new drug development,” said Steve Harper, CEO of Veeva Basics.
To meet business and quality control needs, Veeva Basics adds two new applications:
- Veeva LIMS Basics for virtual businesses to enable oversight of contract manufacturing organizations, including batch release and certificate of analysis (CoA) capabilities. The stability feature is planned for 2026.
- VeevaPromoMats Basics for complete content lifecycle management, including approval, storage and distribution of promotional content and complaints management.
Veeva LIMS (Laboratory Information Management) Basics and PromoMats Basics are expected to be available in early 2026. Built on the proven Vault platform, Veeva Basics applications help customers scale their technology infrastructure as they grow. To learn more about Veeva Basics, please visit veevabasics.com.
What biotech companies are saying about Veeva Basics:
“As a rapidly growing company, we saw the value of Veeva Basics in standardizing our processes based on industry best practices. Knowing we have an agile solution that works today, while providing easy access to the Veeva Vault platform as we grow, gives us peace of mind about our ability to meet future requirements,” said Richard Tornai, Senior Director of IT, Research and Clinical Development at Structure Therapeutics.
“Creating a foundation for our quality and regulatory operations was a priority and we needed a compliant and cost-effective solution for document and records management. We believe Veeva Basics meets these needs and more, providing logical workflows, a library of standard operating procedure templates and forms, and simple, effective training,” said Bryan Ball, director of technical operations at Whitehawk Therapeutics.
“Veeva Basics provided us with a best-in-class solution with global support that allowed us to quickly upskill our staff. Veeva’s commitment to biotechnology innovation and its focus on customer success make it the ideal partner,” said Bernhard Irlinger, Chief Quality Officer at AiCuris.
About Veeva Systems
Veeva provides the life sciences industry cloud with software, data and business consulting. Committed to innovation, product excellence and the success of its partners, Veeva meets the needs of more than 1,500 customers, from the world’s largest biopharmaceutical companies to emerging biotechnology companies. A true public benefit company, Veeva is committed to best reconciling the interests of all the stakeholders with which it collaborates: customers, employees, shareholders and industries. For more information, visit veeva.com/eu.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva’s products and services, as well as the expected results or benefits of using our products and services. These statements are based on our current expectations. Actual results could differ materially from those stated herein, and we undertake no obligation to update these statements. There are numerous risks that could adversely impact our results, including the risks and uncertainties disclosed in our Form 10-Q for the period ending July 31, 2025, which you can view here (a summary of the risks that could impact our business can be found on pages 33 and 34), as well as in our subsequent filings with the SEC, which you can view at sec.gov.
Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
[emailprotected]
Logo- https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo_v2.jpg